En español
NIDA

Amphetamines

New INVEST Drug Abuse Research Fellow Sujung Yoon, M.D., Ph.D., South Korea, will spend 12 months under the mentorship of Perry F. Renshaw, F.M.D., Ph.D., M.B.A., The Brain Institute, University of Utah, to focus on the application of multinuclear magnetic resonance spectroscopy markers of brain health in response to treatment.

Former NIDA International Program Distinguished International Scientist Octavio Campollo, M.D., M.Sci., Ph.D., Mexico, and colleagues report in Drug and Alcohol Dependence that Mexico’s 2004 controls on ephedrine and pseudoephedrine changed the U.S. methamphetamine market. Restrictions on these precursor chemicals in Mexico resulted in widespread emergence of less potent methamphetamine and declines in prevalence and availability of the most potent type of the drug, which had dominated the U.S. market since the late 1980s. The authors found that U.S.

INVEST/Clinical Trials Network (CTN) Fellow Leonardo R. Estacio, Jr., Ph.D., M.P.H., spent his fellowship year focused on behavioral therapies to reduce methamphetamine abuse among adolescent Filipinos.

A new document, published by the United Nations Office on Drugs and Crime (UNODC), reports that the manufacture, trafficking, and consumption of amphetamine-type stimulant (ATS) drugs in Myanmar, one of the largest countries in Southeast Asia, is worsening.